Ann L. Lee

CIK: 0001723629

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (62.5%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PRME

Prime Medicine, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

PRME
Prime Medicine, Inc.
Feb 23, 2026
Award(A)
Stock Option (right to buy)
Direct
375K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
181K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
181K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
181K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
181K shares-
PRME
Prime Medicine, Inc.
May 21, 2025
Purchase(P)
Direct
100K shares at avg. $1.13$113K
PRME
Prime Medicine, Inc.
May 8, 2025
Award(A)
Stock Option (right to buy)
Direct
80.4K shares-
PRME
Prime Medicine, Inc.
Feb 27, 2025
Award(A)
Stock Option (right to buy)
Direct
275K shares-

		Type	Shares	Price		Ownership
Feb 23, 2026	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	375,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	180,995	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	180,995	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	180,995	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	180,995	-	-	Direct
May 21, 2025	PRME Prime Medicine, Inc.	Purchase(P)	100,000	$1.13	$113,000	Direct
May 8, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	80,416	-	-	Direct
Feb 27, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	275,000	-	-	Direct

1-8 of 8 transactions

About LEE ANN L.

LEE ANN L. (SEC CIK 0001723629) files insider reports with the SEC as Chief Technical Officer of Prime Medicine, Inc. (PRME).

Signal8 holds 5 ownership filings by LEE ANN L., all Form 4s, filed between Mar 3, 2025 and Feb 24, 2026. Those filings report 8 transactions, from Feb 27, 2025 to Feb 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on LEE ANN L.'s filings is in CAMBRIDGE, MA.

Recent filings by LEE ANN L.

Feb 23, 2026: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).
Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).
Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).

Other insiders filing for Prime Medicine, Inc. (PRME)

Schenkein David P, Director
Marrazzo Jeffrey D, Director
NELSEN ROBERT, Director
Kelly Michael Aaron, Director
Foster-Cheek Kaye I, Director
Chung Wendy, Director

How to read Form 4 transaction codes